318 results on '"Furtado, Remo"'
Search Results
2. Early versus delayed coronary angiography in patients with out-of-hospital cardiac arrest and no ST-segment elevation: a systematic review and meta-analysis of randomized controlled trials
3. Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials
4. Cardiovascular Safety of Azithromycin in Patients Hospitalized With COVID-19: A Prespecified Pooled Analysis of the COALITION I and COALITION II Randomized Clinical Trials
5. Comparison between two different local hemostatic methods for dental extractions in patients on dual antiplatelet therapy: a within-person, single-blind, randomized study
6. Abstract 13057: The Role of Ischemic and Bleeding Scores in Patients With Acute Coronary Syndromes Submitted to Coronary Surgical Revascularization During the Same Hospitalization
7. Abstract 12946: Among Patients With Acute Coronary Syndromes, is the Risk of Hyperglycemia for In-Hospital Mortality Similar in Men and Women?
8. Biomarker Prediction of Complex Coronary Revascularization Procedures in the FOURIER Trial
9. Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction
10. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial
11. Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)–Coalition IV trial
12. Abstract 10481: The Effect of Current Smoking on Platelet Reactivity Measures by Point-of-Care Methods in Patients Treated With and Without Clopidogrel
13. Abstract 10464: In-Hospital and Long-Term Impact of Right and Left Bundle-Branch Block in Mortality in Patients With Acute Myocardial Infarction
14. Platelet Reactivity in Patients With Acute Coronary Syndromes Awaiting Surgical Revascularization
15. Platelet Reactivity and Coagulation Markers in Patients with COVID-19
16. Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization
17. Editorial: Exploring modern approaches to address critical care challenges in risk stratification for cardiology
18. Relation of High Lipoprotein (a) Concentrations to Platelet Reactivity in Individuals with and Without Coronary Artery Disease
19. What Lessons Have We Learned and What Remains to be Clarified for PCSK9 Inhibitors? A Review of FOURIER and ODYSSEY Outcomes Trials
20. Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial
21. Platelet function, coagulation and fibrinolysis in patients with previous coronary and cerebrovascular ischemic events
22. Long-term outcomes among stable post-acute myocardial infarction patients living in rural versus urban areas: insights from the prospective, observational TIGRIS registry
23. Is adenosine associated with sudden death in schizophrenia? A new framework linking the adenosine pathway to risk of sudden death
24. Increased bodyweight and inadequate response to aspirin in individuals with coronary artery disease
25. Early versus delayed coronary angiography in patients with out-of-hospital cardiac arrest and no ST-segment elevation: a systematic review and meta-analysis of randomized controlled trials
26. Abstract 16688: Effects of Evolocumab in Patients With Prior Percutaneous Coronary Intervention: An Analysis From the Fourier Trial
27. Abstract 14770: Reduction With Evolocumab in Complex Coronary Disease Requiring Revascularization: Insights From the FOURIER Trial
28. Effects of exercise on platelet reactivity after myocardial infarction: a randomized clinical trial.
29. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58
30. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial
31. The Use of Oral Beta-Blockers and Clinical Outcomes in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: a Long-Term Follow-Up Study
32. Anticoagulation Strategies in Non-Critically Ill Patients Hospitalized with COVID-19: A Randomized Clinical Trial
33. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
34. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction: Subanalysis From the DECLARE-TIMI 58 Trial
35. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
36. Effects of exercise on platelet reactivity after myocardial infarction: a randomized clinical trial
37. Long‐term mortality after acute coronary syndromes among patients with normal, mildly reduced, or reduced ejection fraction
38. The great discovery of DOACs and why physicians insist on misusing it: A paradox of the 21 century
39. Effects of DPP4 Inhibitor in Platelet Reactivity and Other Cardiac Risk Markers in Patients with Type 2 Diabetes and Acute Myocardial Infarction
40. Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment–Elevation Myocardial Infarction: Results of REAL-TIMI 63B
41. Influenza vaccination strategy in acute coronary syndromes: the VIP-ACS trial
42. Drug Interaction Between Clopidogrel and Ranitidine or Omeprazole in Stable Coronary Artery Disease: A Double-Blind, Double Dummy, Randomized Study
43. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial
44. Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection
45. Long‐term mortality after acute coronary syndromes among patients with normal, mildly reduced, or reduced ejection fraction.
46. Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention
47. P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials
48. Dapagliflozin in patients with COVID-19: mind the kidneys – Authors' reply
49. Abstract 12524: Very Long-term Mortality After St Elevation Myocardial Infarction (stemi) Complicated By Cardiogenic Shock
50. Abstract 10724: Long-Term Mortality After Acute Coronary Syndromes Among Patients with Normal, Mid-Range or Low Ejection Fraction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.